A Phase 4 interventional study of Aqueous Suppressant Eye Drops in Glaucoma, sponsored by Credit Valley EyeCare. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-21.
Sponsored by Credit Valley EyeCare · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing timolol in Glaucoma — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma.
Among the 28 studies testing timolol in Glaucoma, this one is the 8th largest by planned enrollment, is the only one that started in 2012, is one of 13 in phase 4, and was the 13th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 28 studies testing timolol in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 60 across the 28 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 28 have an industry lead sponsor. The 10 most frequent:
Credit Valley EyeCare is the lead sponsor of 4 studies on the registry; none are open to participants now.
Credit Valley EyeCare has 3 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing timolol in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
After implantation of an Ahmed glaucoma valve in patients with glaucoma, hyperencapsulation phase is an unwanted postoperative phenomenon, typically occurring with the free 3 months postoperatively. When this does occur, it is treated with aqueous suppressant eye drops.
This study aims to determine if it is possible to reduce the rate of hyperencapsulation phase. Patients in the treatment group will receive aqueous suppressant eye drops before the hyperencapsulation phase starts. Treatment will be initiated once their intraocular pressure is above a pre-defined level, and will target a pre-defined range.
Patients with glaucoma requiring tube shunt surgery, with or without simultaneous cataract surgery, will be enrolled in this prospective randomized controlled study at ten sites across Canada and the United States (to be determined). Patients with highly advanced glaucoma at high risk of fixation loss, neovascular glaucoma, chronic uveitis, marked corneal disease, sulfa allergy, renal disease or any contraindication to diamox use will be excluded.
Patients scheduled for Ahmed glaucoma valve surgery, with or without cataract surgery, will be randomized using a stratified central block randomization approach to the treatment group or control group. Those scheduled for combined cataract and tube shunt will be randomized separately from those receiving tube shunt alone. Surgeons will be masked to the postoperative treatment or control group at the time of surgery since randomization will occur when the patient is one-week postoperative Those in the treatment group would receive short-term prophylactic aqueous suppression for the first 3 postoperative months to maintain intraocular pressure (IOP) between 7 and 10mmHg. The control group would not receive prophylactic aqueous suppression, but would be treated using a similar protocol as the treatment group in the event that an Hyperencapsulation phase (HEP) endpoint is met.
Prophylactic aqueous suppression in the study group would only be given for the 1st 3 months postoperatively. At the 3 month visit, aqueous suppression will be stopped. The primary outcome measure is washout IOP at 4 months postoperative. Washout IOP will be checked one month after discontinuation (earlier if needed i.e., advanced glaucoma patients).
Beyond 3 months, aqueous suppressants would be used at the clinician's discretion based on IOP.
At the conclusion of the study, the 4-month postoperative washout IOP, the incidence of HEP, the 12-month IOP, the 13-month washout IOP, and medication requirement would be compared between the treatment and control arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
Drug: Aqueous Suppressant Eye Drops
Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates. (If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)
Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID). Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID). Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)
Also known as: Timoptic, Trusopt, Azopt, Alphagan-P, Xalatan, Travatan Z, Lumigan, Diamox
Intraocular pressure
The primary outcome measure is intraocular pressure (IOP) at 4 months postoperative. This will be a washout IOP (i.e. all glaucoma eye drops will be stopped at 3 months postoperative in all study patients)
Time frame: 4 months postoperative
Hyperencapsulation phase (HEP)
The HEP endpoint will be met within the first 3 postoperative months if all of the following are met: 1. IOP increase by 5mmHg or greater compared to previous visit 2. A bleb appearance in keeping with encapsulation (raised, thickened, firm, dome-shaped) 3. no other reason for IOP increase
Time frame: first 3 months postoperative
Qualified Ahmed Glaucoma Valve success
An eye will have qualified success of the Ahmed glaucoma valve if the intraocular pressure (IOP) is at or below 18mmHg at 12 months with use of medications.
Time frame: 12 months
Absolute Ahmed Glaucoma Valve success
An eye will have absolute success of the Ahmed glaucoma valve if the intraocular pressure (IOP) is at or below 18mmHg at 13 months without use of medications. Medications will be stopped at the 12 month visit, and so eyes will be washed out at 13 months.
Time frame: 13 months
Number of glaucoma medications
Will count the number of glaucoma medication classes required to achieve qualified Ahmed Glaucoma Valve success at 12 months.
Time frame: 12 months
The record gives a start of Feb 2012, a primary completion of Jun 2018 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Timolol
Credit Valley EyeCare